Sign up to save your podcasts
Or
Share HLH, CXCL9 and Clinical Decision-Making with Dr. Joe Rocco
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
HLH, CXCL9 and Clinical Decision-Making with Dr. Joe Rocco
In this episode, our Medical Director, Dr. Brad Lewis, talks with Dr. Joe Rocco, a NIAID Assistant Clinical Investigator who specializes in Hemophagocytic Lymphohistiocytosis (HLH).
Dr. Lewis and Dr. Rocco discuss HLH and the evolving approach to recognizing and managing this life-threatening hyperinflammatory syndrome. The conversation focuses on early clinical recognition, the role of CXCL9 as a dynamic marker of interferon-gamma activity, and how recent multicenter data support using CXCL9 to stratify risk, guide treatment urgency, and improve outcomes in critically ill patients.
Click for more information on our HLH Genetic Panel or visit us at MachaonDiagnostics.com.
View all episodes
By Dr. Brad Lewis, Machaon DiagnosticsIn this episode, our Medical Director, Dr. Brad Lewis, talks with Dr. Joe Rocco, a NIAID Assistant Clinical Investigator who specializes in Hemophagocytic Lymphohistiocytosis (HLH).
Dr. Lewis and Dr. Rocco discuss HLH and the evolving approach to recognizing and managing this life-threatening hyperinflammatory syndrome. The conversation focuses on early clinical recognition, the role of CXCL9 as a dynamic marker of interferon-gamma activity, and how recent multicenter data support using CXCL9 to stratify risk, guide treatment urgency, and improve outcomes in critically ill patients.
Click for more information on our HLH Genetic Panel or visit us at MachaonDiagnostics.com.